So a cap raise at current market levels would be 960million shares on issue and a market cap of $50million AUD and infact makes market cap calculations pretty easy going forward (HA).
They've at least given us a breakdown of where the capital is going:
Expanding US Sales team A$2mio
R&D (PRIZMA G3) 1.2mio
Production of $7mio
Monitoring and infrastructure $2mio
and working capital $2mio.
Will see what the 4c brings, very hard to get a read on how sales are going, whether the IDTF facilities have normalised or any other progress with current opportunities. Given current information id say this gets raised below 5c a share
Unfortunately, to get the company to a position where it can grow and is not hampered by cash constraints, i think they do need a raise of this size. My issue with the company is execution - but if they dont raise, this could likely just fade away into darkness.
In startup terms, this looks like a Series B where the company is gaining some traction with products and needs the growth capital to accelerate sales.
This one is for the long haul now given that dilution
- Forums
- ASX - By Stock
- GMV
- Ann: Notice of Annual General Meeting
Ann: Notice of Annual General Meeting, page-11
-
- There are more pages in this discussion • 442 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add GMV (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online